|
Karl Handelsman is the Founder and General Partner of Codon Capital, established in 2013 to invest in early-stage biotech teams uniquely qualified to build breakthrough technical solutions in therapeutics and synthetic biology. Karl gained unique experience to his approach while also serving as Senior Advisor, Roche Venture Fund from 2016 – Jan 2021. Karl was previously a Managing Director at CMEA Ventures, a major venture fund where he led biotech investments (managing four funds in size from $40M to $400M) over 14 years. In previous business development roles, Karl worked at Tularik and Millennium. He is Chairman of the Board of Good Therapeutics, a company building a new class of protein drugs that are only active when bound to a target molecule. Karl received an MBA from the Sloan School of Business, MIT, an MS in genetics from Harvard Medical School, and a BA from Boston University.
|
Mitchell Mutz, Ph.D., joined Codon Capital as Partner in 2020 where he is responsible for sourcing, leading and managing investments. Previously, he was Senior Investment Director, Roche Venture Fund, the corporate venture arm of Roche, Inc. In addition, Mitchell was a founder and president of Amplyx Pharmaceuticals, Inc., a biotherapeutics company that progressed from concept to clinical stage under his guidance. He was also on the founding team and the Principal Scientist of Labcyte (now part of Beckman Coulter, Inc.), a tools company that he helped grow from a garage-based start-up to profitability. Mitchell earned a Ph.D. in chemistry from the University of Rochester, a diploma in orchestral studies from the University of London, and a B.A. in chemistry from Oberlin College. He is also an inventor on 37 issued patents.
|